Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (161-170 of 545) with videos related to

Pageof 55
Sort By:
The Journal of Clinical Ethics|January 1, 1992
Ethical difficulties with randomized clinical trials involving cancer patients: examples from the field of gynecologic oncologyM Markman
Current Opinion in Oncology|October 1, 1992
Systemic therapy for gynecologic cancerM Markman
Cancer Investigation|January 1, 1995
The objective clinical scientist versus the advocate: a complex ethical and political dilemma facing cancer investigators and the publicM Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
Supportive careM Markman
Cancer Investigation|January 1, 1994
When regulatory requirements conflict with ethical study design: the case of oral ondansetronM Markman
Gynecologic Oncology|June 1, 1994
Resetting the CA-125 range for a complete response to chemotherapy: why?M Markman
Seminars in Oncology|October 23, 1998
Amifostine in reducing cisplatin toxicityM Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
Supportive careM Markman
CA: a Cancer Journal for Clinicians|November 1, 1986
The ethical dilemma of phase I clinical trialsM Markman
Cancer Treatment and Research|July 18, 2007
Current status of intraperitoneal antineoplastic drug deliveryM Markman
Pageof 55

Showing results (161-170 of 545) with videos related to

Sort By:
Pageof 55
The Journal of Clinical Ethics|January 1, 1992
Ethical difficulties with randomized clinical trials involving cancer patients: examples from the field of gynecologic oncologyM Markman
Current Opinion in Oncology|October 1, 1992
Systemic therapy for gynecologic cancerM Markman
Cancer Investigation|January 1, 1995
The objective clinical scientist versus the advocate: a complex ethical and political dilemma facing cancer investigators and the publicM Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
Supportive careM Markman
Cancer Investigation|January 1, 1994
When regulatory requirements conflict with ethical study design: the case of oral ondansetronM Markman
Gynecologic Oncology|June 1, 1994
Resetting the CA-125 range for a complete response to chemotherapy: why?M Markman
Seminars in Oncology|October 23, 1998
Amifostine in reducing cisplatin toxicityM Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
Supportive careM Markman
CA: a Cancer Journal for Clinicians|November 1, 1986
The ethical dilemma of phase I clinical trialsM Markman
Cancer Treatment and Research|July 18, 2007
Current status of intraperitoneal antineoplastic drug deliveryM Markman
Pageof 55